CyFlow CD44 PE
品番 | BL125284 | ||
---|---|---|---|
抗体名 | Anti-Hu CD44 PE,MEM-85 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 2 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG2b PE (CP922237) |
||
反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
抗原 | CD44, H-CAM, Pgp-1 | 最大蛍光波長 | 576 nm |
クローン | MEM-85 | 最大励起波長 | 496 nm, 565 nm |
ホスト | Mouse | 標識/Format | PE |
アイソタイプ | IgG2b | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD44 PE,MEM-85
特異性
The mouse monoclonal antibody MEM-85 recognizes both cell surface-expressed and soluble form of CD44 antigen, a 80-95 kDa transmembrane glycoprotein (hyaladherin family) present on the most of cells and tissues (leukocytes, endothelial cells, mesenchymal cells, etc.); it is negative on platelets and hepatocytes.
抗原情報
CD44 is a transmembrane glycoprotein expressed on the surface of most cells, which serves as a receptor for hyaluronan. CD44 mediates angiogenesis, cell adhesion, proliferation and migration, it is thus important for lymphocyte activation, recirculation and homing, it can thus serve e.g. as a modulator of macrophage recruitment in response to pathogen. Although CD44 functions are essential for physiological activities of normal cells, elevated CD44 expression correlates with poor prognosis in many carcinomas, facilitating tumor growth and metastasis, antiapoptosis and directional motility of cancer cells.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bazil V, Strominger JL: Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes: Induction of cleavage of L‑selectin via CD16. J·Immunol. 1994·Feb·1; 152(3):1314‑22. <·PMID:·7507963·>
• Holleman A, den Boer ML, Cheok MH, Kazemier KM, Pei D, Downing JR, Janka-Schaub GE, Göbel U, Graubner UB, Pui CH, Evans WE, Pieters R: Expression of the outcome predictor in acute leukemia 1 (OPAL1 gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood. 2006·Sep·15; 108(6):1984‑90. <·PMID:·16709928·>
• Ide K, Wang H, Tahara H, Liu J, Wang X, Asahara T, Sykes M, Yang YG, Ohdan H: Role for CD47‑SIRPalpha signaling in xenograft rejection by macrophages. Proc·Natl·Acad·Sci·USA. 2007·Mar·20; 104(12):5062‑6. <·PMID:·17360380·>
• Kolar GR, Mehta D, Pelayo R, Capra JD: A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007·Mar·15; 109(6):2545‑52. <·PMID:·17132718·>
• Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO: Ep‑CAM: a human epithelial antigen is a homophilic cell‑cell adhesion molecule. J·Cell·Biol. 1994·Apr; 125(2):437‑46. <·PMID:·8163559·>
• Schmidt CS, Liu J, Zhang T, Song HY, Sandusky G, Mintze K, Benschop RJ, Glasebrook A, Yang DD, Na S: Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J·Exp·Med. 2003·Jan·6; 197(1):51‑62. <·PMID:·12515813·>
• Stefanová I, Hilgert I, Bazil V, Kristofová H, Horejsí V: Human leucocyte surface glycoprotein CDw44 and lymphocyte homing receptor are identical molecules. Immunogenetics. 1989; 29(6):402‑4. <·PMID:·2659502·>
• Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A: CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, andnormal bone marrow display different apoptosis and drug resistance‑associated phenotypes. Clin·Cancer·Res. 2004·Nov·15; 10(22):7599‑606. <·PMID:·15569991·>
• Subramaniam V, Gardner H, Jothy S: Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp·Mol·Pathol. 2007·Dec; 83(3):341‑6. <·PMID:·17945213·>
• Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL: Immune regulation and vascular inflammation in genetic hypertension. Am·J·Physiol·Heart·Circ·Physiol. 2010·Mar; 298(3):H938‑44. <·PMID:·20044442·>
• Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford·University·Press,·Oxford. 1989; 1‑1820. <·NLM·ID:·8914679·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN